JP2024542682A5 - - Google Patents
Info
- Publication number
- JP2024542682A5 JP2024542682A5 JP2024532418A JP2024532418A JP2024542682A5 JP 2024542682 A5 JP2024542682 A5 JP 2024542682A5 JP 2024532418 A JP2024532418 A JP 2024532418A JP 2024532418 A JP2024532418 A JP 2024532418A JP 2024542682 A5 JP2024542682 A5 JP 2024542682A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163285044P | 2021-12-01 | 2021-12-01 | |
| US63/285,044 | 2021-12-01 | ||
| US202263374222P | 2022-08-31 | 2022-08-31 | |
| US63/374,222 | 2022-08-31 | ||
| PCT/EP2022/083952 WO2023099622A1 (en) | 2021-12-01 | 2022-11-30 | Treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024542682A JP2024542682A (ja) | 2024-11-15 |
| JP2024542682A5 true JP2024542682A5 (https=) | 2025-12-08 |
| JPWO2023099622A5 JPWO2023099622A5 (https=) | 2025-12-08 |
Family
ID=84688213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024532418A Pending JP2024542682A (ja) | 2021-12-01 | 2022-11-30 | 治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250333504A1 (https=) |
| EP (1) | EP4441096A1 (https=) |
| JP (1) | JP2024542682A (https=) |
| KR (1) | KR20240114759A (https=) |
| AU (1) | AU2022402322A1 (https=) |
| IL (1) | IL312981A (https=) |
| MX (1) | MX2024006799A (https=) |
| TW (1) | TW202330589A (https=) |
| WO (1) | WO2023099622A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202519257A (zh) | 2023-08-01 | 2025-05-16 | 英商英美偌科有限公司 | 治療皮膚黑色素瘤之方法 |
| TW202544042A (zh) | 2024-03-13 | 2025-11-16 | 英商英美偌科有限公司 | 治療prame陽性癌症之方法 |
| WO2025224692A1 (en) | 2024-04-25 | 2025-10-30 | Immunocore Limited | Method of treating cancer using a gene expression signature |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002321581C1 (en) | 2001-08-31 | 2008-09-18 | Adaptimmune Limited | Soluble T cell receptor |
| GB201223172D0 (en) | 2012-12-21 | 2013-02-06 | Immunocore Ltd | Method |
| WO2017208018A1 (en) * | 2016-06-02 | 2017-12-07 | Immunocore Limited | Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein |
| GB201709866D0 (en) | 2017-06-20 | 2017-08-02 | Immunocore Ltd | T cell receptors |
-
2022
- 2022-11-30 KR KR1020247021027A patent/KR20240114759A/ko active Pending
- 2022-11-30 IL IL312981A patent/IL312981A/en unknown
- 2022-11-30 AU AU2022402322A patent/AU2022402322A1/en active Pending
- 2022-11-30 EP EP22830692.4A patent/EP4441096A1/en active Pending
- 2022-11-30 MX MX2024006799A patent/MX2024006799A/es unknown
- 2022-11-30 US US18/716,126 patent/US20250333504A1/en active Pending
- 2022-11-30 JP JP2024532418A patent/JP2024542682A/ja active Pending
- 2022-11-30 WO PCT/EP2022/083952 patent/WO2023099622A1/en not_active Ceased
- 2022-12-01 TW TW111146224A patent/TW202330589A/zh unknown